REDUCE LAP-HF II

Conditions

Diseases of the Cardiovascular System

What is the purpose of this trial?

The primary objective of this randomized controlled clinical trial is to evaluate the clinical efficacy and safety of the IASD System II in symptomatic heart failure patients with an LV ejection fraction ≥40%, and elevated left sided filling pressures despite standard Guideline Directed Medical Therapy (GDMT).

  • Trial with
    Corvia Medical, Inc.
  • Start Date
    07/25/2017
  • End Date
    09/29/2019

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Juan Carmona

  • Last Updated
    02/22/2018
  • Study HIC
    #2000020740